 Mary Demoruelle
Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 59 | 2025 | 1006 | 10.340 |
Why?
| | Autoantibodies | 35 | 2025 | 1350 | 4.790 |
Why?
| | Anti-Citrullinated Protein Antibodies | 18 | 2025 | 94 | 4.790 |
Why?
| | Lung Diseases, Interstitial | 10 | 2024 | 495 | 2.780 |
Why?
| | Immunoglobulin A | 10 | 2023 | 166 | 2.490 |
Why?
| | Extracellular Traps | 4 | 2023 | 40 | 2.300 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2023 | 501 | 2.210 |
Why?
| | Connective Tissue Diseases | 4 | 2023 | 71 | 2.200 |
Why?
| | Peptides, Cyclic | 13 | 2023 | 252 | 2.060 |
Why?
| | Immunity, Mucosal | 4 | 2020 | 84 | 1.820 |
Why?
| | Sputum | 4 | 2021 | 286 | 1.770 |
Why?
| | Autoimmunity | 11 | 2025 | 815 | 1.730 |
Why?
| | Rheumatoid Factor | 12 | 2025 | 160 | 1.010 |
Why?
| | Antiphospholipid Syndrome | 1 | 2023 | 26 | 0.860 |
Why?
| | Citrullination | 3 | 2020 | 12 | 0.820 |
Why?
| | Bronchial Diseases | 2 | 2013 | 35 | 0.810 |
Why?
| | Microbiota | 3 | 2021 | 648 | 0.730 |
Why?
| | Citrulline | 3 | 2020 | 39 | 0.730 |
Why?
| | Inflammation | 5 | 2022 | 2465 | 0.690 |
Why?
| | Humans | 66 | 2025 | 114075 | 0.660 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2022 | 220 | 0.650 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2023 | 787 | 0.600 |
Why?
| | Autoantigens | 4 | 2022 | 396 | 0.600 |
Why?
| | Lung | 8 | 2023 | 3521 | 0.590 |
Why?
| | Pedigree | 2 | 2020 | 460 | 0.560 |
Why?
| | Lung Diseases | 2 | 2013 | 690 | 0.520 |
Why?
| | Pneumonia | 1 | 2020 | 563 | 0.470 |
Why?
| | Middle Aged | 29 | 2025 | 26620 | 0.430 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 75 | 0.390 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 103 | 0.390 |
Why?
| | Arthritis | 1 | 2012 | 109 | 0.380 |
Why?
| | Aged | 18 | 2022 | 18973 | 0.380 |
Why?
| | Risk Factors | 15 | 2022 | 8612 | 0.380 |
Why?
| | Respiration Disorders | 2 | 2022 | 68 | 0.380 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 381 | 0.370 |
Why?
| | Female | 35 | 2025 | 59346 | 0.370 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.370 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 122 | 0.370 |
Why?
| | Male | 33 | 2025 | 55416 | 0.360 |
Why?
| | Case-Control Studies | 9 | 2025 | 3007 | 0.350 |
Why?
| | Antirheumatic Agents | 1 | 2012 | 255 | 0.340 |
Why?
| | Adult | 24 | 2025 | 30394 | 0.340 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 286 | 0.330 |
Why?
| | Prospective Studies | 12 | 2025 | 6198 | 0.300 |
Why?
| | Histones | 3 | 2021 | 529 | 0.290 |
Why?
| | Neutrophils | 2 | 2023 | 1089 | 0.280 |
Why?
| | Epitopes | 5 | 2023 | 434 | 0.270 |
Why?
| | Disease Progression | 7 | 2021 | 2371 | 0.260 |
Why?
| | Chlamydia trachomatis | 1 | 2025 | 38 | 0.240 |
Why?
| | Intestines | 2 | 2021 | 325 | 0.240 |
Why?
| | Chlamydia Infections | 1 | 2025 | 66 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2090 | 0.220 |
Why?
| | Adenylate Kinase | 1 | 2023 | 26 | 0.220 |
Why?
| | Antibody Formation | 3 | 2022 | 266 | 0.220 |
Why?
| | Incidence | 5 | 2021 | 2314 | 0.210 |
Why?
| | Dysbiosis | 2 | 2020 | 145 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 72 | 0.180 |
Why?
| | Hydrolases | 1 | 2021 | 51 | 0.180 |
Why?
| | Neutrophil Activation | 1 | 2021 | 78 | 0.180 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 84 | 0.180 |
Why?
| | Vimentin | 1 | 2020 | 58 | 0.170 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.170 |
Why?
| | Early Diagnosis | 3 | 2022 | 217 | 0.170 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.170 |
Why?
| | Milk Proteins | 1 | 2020 | 36 | 0.170 |
Why?
| | Mucin-5B | 1 | 2022 | 184 | 0.170 |
Why?
| | Bacteriophages | 1 | 2021 | 75 | 0.170 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 167 | 0.170 |
Why?
| | Muramidase | 1 | 2020 | 72 | 0.170 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 180 | 0.170 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 81 | 0.170 |
Why?
| | Acetaldehyde | 1 | 2019 | 15 | 0.160 |
Why?
| | Malondialdehyde | 1 | 2019 | 28 | 0.160 |
Why?
| | Mammary Glands, Animal | 1 | 2020 | 117 | 0.160 |
Why?
| | Biomarkers | 5 | 2021 | 3397 | 0.160 |
Why?
| | Occupational Exposure | 1 | 2022 | 256 | 0.160 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 119 | 0.160 |
Why?
| | Family Characteristics | 1 | 2020 | 151 | 0.160 |
Why?
| | Immunoglobulin G | 5 | 2023 | 766 | 0.160 |
Why?
| | Nuclear Family | 1 | 2019 | 48 | 0.160 |
Why?
| | Lactation | 1 | 2020 | 149 | 0.160 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 130 | 0.150 |
Why?
| | Monocytes | 1 | 2020 | 503 | 0.150 |
Why?
| | Mucous Membrane | 1 | 2018 | 108 | 0.150 |
Why?
| | Prevalence | 2 | 2022 | 2247 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2016 | 46 | 0.130 |
Why?
| | Complement System Proteins | 1 | 2019 | 282 | 0.130 |
Why?
| | Plasma Cells | 1 | 2016 | 56 | 0.130 |
Why?
| | Peptides | 1 | 2021 | 847 | 0.130 |
Why?
| | Mitochondria | 1 | 2021 | 744 | 0.130 |
Why?
| | Animals | 5 | 2023 | 31570 | 0.120 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 4403 | 0.120 |
Why?
| | Young Adult | 3 | 2021 | 10458 | 0.120 |
Why?
| | Mice | 4 | 2023 | 14847 | 0.120 |
Why?
| | Molecular Mimicry | 1 | 2014 | 35 | 0.120 |
Why?
| | Immunoglobulin M | 3 | 2022 | 245 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 489 | 0.110 |
Why?
| | Mass Screening | 1 | 2020 | 979 | 0.110 |
Why?
| | Mouth Mucosa | 1 | 2014 | 79 | 0.110 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 7 | 0.110 |
Why?
| | Stress, Psychological | 1 | 2020 | 944 | 0.100 |
Why?
| | Prognosis | 2 | 2021 | 3315 | 0.100 |
Why?
| | Population Surveillance | 1 | 2015 | 385 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1690 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2013 | 281 | 0.100 |
Why?
| | Arthrography | 1 | 2011 | 18 | 0.100 |
Why?
| | Age Factors | 1 | 2019 | 2886 | 0.100 |
Why?
| | Remission Induction | 1 | 2012 | 233 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2022 | 9049 | 0.100 |
Why?
| | Blood Pressure | 1 | 2017 | 1531 | 0.090 |
Why?
| | Time-to-Treatment | 1 | 2012 | 146 | 0.090 |
Why?
| | Joints | 1 | 2011 | 83 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1078 | 0.090 |
Why?
| | Time Factors | 3 | 2020 | 6077 | 0.090 |
Why?
| | Air Pollution | 1 | 2013 | 169 | 0.090 |
Why?
| | Disease Susceptibility | 2 | 2021 | 316 | 0.080 |
Why?
| | Vital Capacity | 2 | 2022 | 254 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1331 | 0.080 |
Why?
| | Organ Specificity | 2 | 2019 | 266 | 0.070 |
Why?
| | Cohort Studies | 3 | 2022 | 4884 | 0.060 |
Why?
| | Family | 2 | 2021 | 589 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1128 | 0.060 |
Why?
| | Switzerland | 1 | 2025 | 20 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1422 | 0.060 |
Why?
| | Smoking | 2 | 2024 | 1382 | 0.060 |
Why?
| | Telomere Shortening | 1 | 2024 | 17 | 0.060 |
Why?
| | Azathioprine | 1 | 2022 | 49 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.050 |
Why?
| | Rituximab | 1 | 2022 | 148 | 0.050 |
Why?
| | Telomere | 1 | 2024 | 202 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 124 | 0.050 |
Why?
| | Cytokines | 2 | 2020 | 1824 | 0.050 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 39 | 0.050 |
Why?
| | Arthralgia | 1 | 2021 | 46 | 0.050 |
Why?
| | Vitamins | 1 | 2022 | 150 | 0.050 |
Why?
| | Genetic Markers | 1 | 2022 | 320 | 0.050 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 69 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 56 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 229 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 62 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 121 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 396 | 0.040 |
Why?
| | Prolactin | 1 | 2020 | 96 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 274 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 175 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4092 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 211 | 0.040 |
Why?
| | Vitamin D | 1 | 2022 | 340 | 0.040 |
Why?
| | Methotrexate | 1 | 2020 | 227 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 368 | 0.040 |
Why?
| | Arginine | 1 | 2020 | 236 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2022 | 641 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 522 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 520 | 0.040 |
Why?
| | Tobacco Products | 1 | 2019 | 98 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4392 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 381 | 0.040 |
Why?
| | Gene Frequency | 1 | 2019 | 476 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 429 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 475 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 399 | 0.040 |
Why?
| | Phylogeny | 1 | 2021 | 787 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2021 | 673 | 0.040 |
Why?
| | Environment | 1 | 2019 | 333 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 6 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 10 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 14 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.030 |
Why?
| | Proteome | 1 | 2020 | 337 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 338 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 789 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 59 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1257 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 12521 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 86 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 694 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2015 | 60 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 721 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 413 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 951 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1417 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1206 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 815 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 143 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 471 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2388 | 0.030 |
Why?
| | Risk | 1 | 2016 | 810 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 722 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 437 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2540 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 813 | 0.030 |
Why?
| | United States | 2 | 2022 | 12143 | 0.030 |
Why?
| | Geographic Information Systems | 1 | 2013 | 37 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2550 | 0.030 |
Why?
| | Cell Membrane | 1 | 2016 | 670 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2020 | 3862 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2016 | 459 | 0.030 |
Why?
| | Body Mass Index | 1 | 2019 | 1957 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 1880 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2958 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1638 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3338 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 568 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 185 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 1641 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 255 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 362 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2322 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2272 | 0.020 |
Why?
| | Adolescent | 1 | 2021 | 17810 | 0.010 |
Why?
|
|
Demoruelle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|